253 related articles for article (PubMed ID: 34244312)
21. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
22. Targeted immune epitope prediction to HHLA2 and MAGEB5 protein variants as therapeutic approach to related viral diseases.
Achinko DA; Dormer A; Narayanan M; Norman EF
BMC Immunol; 2021 Jul; 22(1):49. PubMed ID: 34320928
[TBL] [Abstract][Full Text] [Related]
23. HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells.
Guo H; Zhang C; Tang X; Zhang T; Liu Y; Yu H; Li Y; Wang R
Inflammation; 2022 Aug; 45(4):1585-1599. PubMed ID: 35175496
[TBL] [Abstract][Full Text] [Related]
24. HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families.
Janakiram M; Chinai JM; Zhao A; Sparano JA; Zang X
Oncoimmunology; 2015 Aug; 4(8):e1026534. PubMed ID: 26405587
[TBL] [Abstract][Full Text] [Related]
25. Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Wang R; Guo H; Tang X; Zhang T; Liu Y; Zhang C; Yu H; Li Y
Inflammation; 2022 Feb; 45(1):308-330. PubMed ID: 34536158
[TBL] [Abstract][Full Text] [Related]
26. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
27. Blockade of the immunosuppressive KIR2DL5/PVR pathway elicits potent human NK cell-mediated antitumor immunity.
Ren X; Peng M; Xing P; Wei Y; Galbo PM; Corrigan D; Wang H; Su Y; Dong X; Sun Q; Li Y; Zhang X; Edelmann W; Zheng D; Zang X
J Clin Invest; 2022 Nov; 132(22):. PubMed ID: 36377656
[TBL] [Abstract][Full Text] [Related]
28. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
29. Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer.
Lv C; Han S; Wu B; Liang Z; Li Y; Zhang Y; Lang Q; Zhong C; Fu L; Yu Y; Xu F; Tian Y
Front Immunol; 2022; 13():984172. PubMed ID: 36159808
[TBL] [Abstract][Full Text] [Related]
30. Regulation of KIR3DL3 Expression via Mirna.
Nutalai R; Gaudieri S; Jumnainsong A; Leelayuwat C
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31405037
[TBL] [Abstract][Full Text] [Related]
31. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).
Purdy AK; Campbell KS
Cancer Biol Ther; 2009 Dec; 8(23):2211-20. PubMed ID: 19923897
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.
Wang B; Ran Z; Liu M; Ou Y
Front Immunol; 2019; 10():1573. PubMed ID: 31379814
[TBL] [Abstract][Full Text] [Related]
33. A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.
Xiao Y; Freeman GJ
Clin Cancer Res; 2015 May; 21(10):2201-3. PubMed ID: 25869386
[TBL] [Abstract][Full Text] [Related]
34. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
[TBL] [Abstract][Full Text] [Related]
35. HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma.
Liao X; Zhang D
Am J Clin Pathol; 2022 Jul; 158(1):62-69. PubMed ID: 35084443
[TBL] [Abstract][Full Text] [Related]
36. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
37. Enhancing Natural Killer and CD8
Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
[TBL] [Abstract][Full Text] [Related]
38. SHP-1- and phosphotyrosine-independent inhibitory signaling by a killer cell Ig-like receptor cytoplasmic domain in human NK cells.
Yusa S; Catina TL; Campbell KS
J Immunol; 2002 May; 168(10):5047-57. PubMed ID: 11994457
[TBL] [Abstract][Full Text] [Related]
39. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
Front Immunol; 2022; 13():902167. PubMed ID: 36003385
[TBL] [Abstract][Full Text] [Related]
40. Homogenous expression of killer cell immunoglobulin-like receptors (KIR) on polyclonal natural killer cells detected by a monoclonal antibody to KIR2D.
Watzl C; Peterson M; Long EO
Tissue Antigens; 2000 Sep; 56(3):240-7. PubMed ID: 11034560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
